Dimerix Draws Down A$17M Under Non-Dilutive Funding Facility
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Dimerix Limited has announced the completion of an initial drawdown under a non-dilutive funding facility, receiving significant financial support for its clinical programs. Dimerix retains the option to access additional funds in the future, enhancing its financial flexibility as it progresses its key projects. This drawdown represents half of the total committed amount available under the facility, which is designed to minimize financing costs while supporting operational needs.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Dimerix
- Dimerix Presents at ASX SMIDcaps Conference 2026
- Waiver of Listing Rule 10.1 Granted
- Dimerix Presents at E&P Healthcare Conference 2026
- Dimerix DMX-652 Granted Mexican Composition of Matter Patent
- Dimerix Investor Presentation
Later from Dimerix
- Notification of 2026 Annual General Meeting Date
- Notification regarding unquoted securities - DXB
- First Patient Reaches Four Years in DMX-200 Clinical Program
- Dimerix at Canaccord Drug & Device and Ignite Conferences
- DMX-200 First 100 Patients Complete Phase 3 Trial Treatment
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix